Jennifer R Head1, Philip A Collender2, Joseph A Lewnard1,3, Nicholas K Skaff2, Ling Li4, Qu Cheng2, Julia M Baker5, Charles Li2, Dehao Chen6, Alison Ohringer2, Song Liang6, Changhong Yang4, Alan Hubbard7, Benjamin Lopman5, Justin V Remais2. 1. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California, USA. 2. Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, California, USA. 3. Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California, USA. 4. Institute for Public Health Information, Sichuan Center for Disease Control and Prevention, Chengdu, China. 5. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. 6. Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA. 7. Division of Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, California, USA.
Abstract
BACKGROUND: Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), associated with severe manifestations of the disease. Pediatric immunization with inactivated EV71 vaccine was initiated in 2016 in the Asia-Pacific region, including China. We analyzed a time series of HFMD cases attributable to EV71, coxsackievirus A16 (CA16), and other enteroviruses in Chengdu, a major transmission center in China, to assess early impacts of immunization. METHODS: Reported HFMD cases were obtained from China's notifiable disease surveillance system. We compared observed postvaccination incidence rates during 2017-2018 with counterfactual predictions made from a negative binomial regression and a random forest model fitted to prevaccine years (2011-2015). We fit a change point model to the full time series to evaluate whether the trend of EV71 HFMD changed following vaccination. RESULTS: Between 2011 and 2018, 279 352 HFMD cases were reported in the study region. The average incidence rate of EV71 HFMD in 2017-2018 was 60% (95% prediction interval [PI], 41%-72%) lower than predicted in the absence of immunization, corresponding to an estimated 6911 (95% PI, 3246-11 542) EV71 cases averted over 2 years. There were 52% (95% PI, 42%-60%) fewer severe HFMD cases than predicted. However, the incidence rate of non-CA16 and non-EV71 HFMD was elevated in 2018. We identified a significant decline in the trend of EV71 HFMD 4 months into the postvaccine period. CONCLUSIONS: We provide the first real-world evidence that programmatic vaccination against EV71 is effective against childhood HFMD and present an approach to detect early vaccine impact or intended consequences from surveillance data.
BACKGROUND:Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), associated with severe manifestations of the disease. Pediatric immunization with inactivated EV71 vaccine was initiated in 2016 in the Asia-Pacific region, including China. We analyzed a time series of HFMD cases attributable to EV71, coxsackievirus A16 (CA16), and other enteroviruses in Chengdu, a major transmission center in China, to assess early impacts of immunization. METHODS: Reported HFMD cases were obtained from China's notifiable disease surveillance system. We compared observed postvaccination incidence rates during 2017-2018 with counterfactual predictions made from a negative binomial regression and a random forest model fitted to prevaccine years (2011-2015). We fit a change point model to the full time series to evaluate whether the trend of EV71 HFMD changed following vaccination. RESULTS: Between 2011 and 2018, 279 352 HFMD cases were reported in the study region. The average incidence rate of EV71 HFMD in 2017-2018 was 60% (95% prediction interval [PI], 41%-72%) lower than predicted in the absence of immunization, corresponding to an estimated 6911 (95% PI, 3246-11 542) EV71 cases averted over 2 years. There were 52% (95% PI, 42%-60%) fewer severe HFMD cases than predicted. However, the incidence rate of non-CA16 and non-EV71 HFMD was elevated in 2018. We identified a significant decline in the trend of EV71 HFMD 4 months into the postvaccine period. CONCLUSIONS: We provide the first real-world evidence that programmatic vaccination against EV71 is effective against childhood HFMD and present an approach to detect early vaccine impact or intended consequences from surveillance data.
Authors: Yu Wang; Zijian Feng; Yang Yang; Steve Self; Yongjun Gao; Ira M Longini; Jon Wakefield; Jing Zhang; Liping Wang; Xi Chen; Lena Yao; Jeffrey D Stanaway; Zijun Wang; Weizhong Yang Journal: Epidemiology Date: 2011-11 Impact factor: 4.822
Authors: Julia M Baker; Jacqueline E Tate; Claudia A Steiner; Michael J Haber; Umesh D Parashar; Benjamin A Lopman Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: Guilherme S Ribeiro; Joice N Reis; Soraia M Cordeiro; Josilene B T Lima; Edilane L Gouveia; Maya Petersen; Kátia Salgado; Hagamenon R Silva; Rosemeire Cobo Zanella; Samanta C Grassi Almeida; Maria Cristina Brandileone; Mitermayer G Reis; Albert I Ko Journal: J Infect Dis Date: 2002-12-13 Impact factor: 5.226
Authors: Hongxia Peng; Zhenhua Chen; Lin Cai; Juan Liao; Ke Zheng; Shuo Li; Xueling Ren; Xiaoxia Duan; Xueqin Tang; Xiao Wang; Lu Long; Chunxia Yang Journal: BMC Public Health Date: 2022-05-17 Impact factor: 4.135
Authors: Sami Salmikangas; Jutta E Laiho; Kerttu Kalander; Mira Laajala; Anni Honkimaa; Iryna Shanina; Sami Oikarinen; Marc S Horwitz; Heikki Hyöty; Varpu Marjomäki Journal: Microorganisms Date: 2020-12-04